Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Emmaus Life Sciences's Business Segments
Emmaus Life Sciences's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Endari US
Total Revenue
$ 12
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Endari US59.2%
- Product and Service Other0.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Endari US | $ 7 | 59.2% |
| Product and Service Other | $ 0 | 0.4% |
Revenue by Product & Service Category - FY
- Endari US82.5%
- Endari International16.8%
- Product and Service Other0.7%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Endari US | $ 2 | 82.5% |
| Endari International | $ 0 | 16.8% |
| Product and Service Other | $ 0 | 0.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Endari US59.2%
- Product and Service Other0.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Endari US | $ 7 | 59.2% |
| Product and Service Other | $ 0 | 0.4% |
Description of Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for rare and orphan diseases. Established in 2000 and headquartered in Torrance, California, Emmaus focuses on addressing unmet medical needs and improving the quality of life for patients.
The company's flagship product is an orally administered prescription pharmaceutical called Xyndari® (also known as L-glutamine oral powder). Xyndari® is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients above the age of SCD is a genetic blood disorder that causes the production of abnormal hemoglobin, resulting in the distortion and breakage of red blood cells.
Xyndari® is the first and only FDA-approved treatment for SCD that has demonstrated reductions in the frequency of painful crises, hospitalizations, and blood transfusions. It works by increasing the availability of free L-glutamine, which helps prevent the sickling of red blood cells, reducing complications associated with SCD. Emmaus has obtained exclusive worldwide rights to Xyndari® and has been granted a 20-year Orphan Drug Exclusivity (ODE) for its use in SCD.
Emmaus Life Sciences has conducted extensive clinical trials to assess the safety and efficacy of Xyndari® in treating SCD. These trials have shown promising results, leading to FDA approval and making Xyndari® an essential treatment option for patients suffering from SCD. Furthermore, the company continues to invest in research and development to explore the potential of Xyndari® in additional indications and expand its therapeutic applications.
In addition to its focus on rare and orphan diseases, Emmaus is committed to addressing global health challenges and supporting underserved populations. The company actively participates in initiatives to raise awareness about SCD and improve access to care for affected individuals. They collaborate with patient advocacy groups, healthcare professionals, and international organizations to promote education, early diagnosis, and comprehensive treatment for SCD patients worldwide.
Emmaus Life Sciences has a dedicated team of researchers, scientists, physicians, and professionals who are committed to advancing medical knowledge and improving patient outcomes. They work in state-of-the-art facilities, leveraging their expertise to develop innovative therapeutic solutions. The company also collaborates with leading academic institutions, research organizations, and pharmaceutical partners to drive scientific advancements and enhance the overall healthcare ecosystem.
With its patient-centric approach, commitment to scientific excellence, and dedication to improving the lives of individuals with rare diseases, Emmaus Life Sciences, Inc. plays a crucial role in the biopharmaceutical industry. Through their innovative research, development, and commercialization efforts, they continue to make significant contributions to the field of rare disease therapeutics and bring hope to patients and their families.
The company's flagship product is an orally administered prescription pharmaceutical called Xyndari® (also known as L-glutamine oral powder). Xyndari® is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients above the age of SCD is a genetic blood disorder that causes the production of abnormal hemoglobin, resulting in the distortion and breakage of red blood cells.
Xyndari® is the first and only FDA-approved treatment for SCD that has demonstrated reductions in the frequency of painful crises, hospitalizations, and blood transfusions. It works by increasing the availability of free L-glutamine, which helps prevent the sickling of red blood cells, reducing complications associated with SCD. Emmaus has obtained exclusive worldwide rights to Xyndari® and has been granted a 20-year Orphan Drug Exclusivity (ODE) for its use in SCD.
Emmaus Life Sciences has conducted extensive clinical trials to assess the safety and efficacy of Xyndari® in treating SCD. These trials have shown promising results, leading to FDA approval and making Xyndari® an essential treatment option for patients suffering from SCD. Furthermore, the company continues to invest in research and development to explore the potential of Xyndari® in additional indications and expand its therapeutic applications.
In addition to its focus on rare and orphan diseases, Emmaus is committed to addressing global health challenges and supporting underserved populations. The company actively participates in initiatives to raise awareness about SCD and improve access to care for affected individuals. They collaborate with patient advocacy groups, healthcare professionals, and international organizations to promote education, early diagnosis, and comprehensive treatment for SCD patients worldwide.
Emmaus Life Sciences has a dedicated team of researchers, scientists, physicians, and professionals who are committed to advancing medical knowledge and improving patient outcomes. They work in state-of-the-art facilities, leveraging their expertise to develop innovative therapeutic solutions. The company also collaborates with leading academic institutions, research organizations, and pharmaceutical partners to drive scientific advancements and enhance the overall healthcare ecosystem.
With its patient-centric approach, commitment to scientific excellence, and dedication to improving the lives of individuals with rare diseases, Emmaus Life Sciences, Inc. plays a crucial role in the biopharmaceutical industry. Through their innovative research, development, and commercialization efforts, they continue to make significant contributions to the field of rare disease therapeutics and bring hope to patients and their families.
Emmaus Life Sciences, Inc. is a biopharmaceutical company that specializes in developing and commercializing innovative therapies for patients with rare and difficult-to-treat medical conditions. The companys primary focus has been on the treatment of sickle cell disease, with a commitment to improving the quality of life for patients through effective and targeted therapeutic solutions.
Segments
1. Sickle Cell Disease: This is the cornerstone of Emmaus Life Sciences research and commercial efforts. Sickle cell disease is a genetic blood disorder characterized by the deformity of red blood cells, leading to severe pain episodes and various complications. Emmaus seeks to address the unmet medical needs within this patient population.
2. Rare Disease Therapeutics: Beyond sickle cell anemia, Emmaus is interested in exploring treatments for other rare diseases, looking to expand its portfolio in the biopharmaceutical market while focusing on conditions with significant patient need and limited treatment options.
3. Research and Development (R&D): The R&D segment is critical to Emmaus, focusing on the clinical development of new therapeutics and the enhancement of existing products. The company actively engages in preclinical and clinical trials to vet potential drug candidates.
Products
1. Endari (L-glutamine oral powder): Endari is Emmaus’ flagship product, specifically developed for the treatment of sickle cell disease in adults and children aged five years and older. This product has been FDA-approved and is designed to decrease the frequency of sickle cell crises and related complications. It works by decreasing oxidative stress in sickle red blood cells and is recommended for routine use in patients with the condition.
2. Pipeline Products: Emmaus maintains a pipeline of potential therapies under development, aimed at addressing other complications of sickle cell disease and possibly other hematologic conditions. The specifics of these pipeline products can vary based on ongoing clinical trials and research outcomes.
3. Potential New Indications: The company is exploring potential additional uses for its existing products and candidates, recognizing that some therapies may have implications for multiple conditions. Ongoing research into the pharmacodynamics and therapeutic benefits of L-glutamine and other compounds may lead to the discovery of new indications.
Services
1. Patient Support Programs: Emmaus understands that navigating chronic conditions like sickle cell disease requires more than medication. The company offers services that support patients in managing their disease effectively. This includes educational resources, counseling, and assistance in accessing care.
2. Clinical Trials Participation: Emmaus often engages with healthcare providers and institutions to facilitate clinical trials for its therapies. This service extends to both medical professionals and patients, ensuring they have access to cutting-edge treatment options while contributing to the advancement of medical research.
3. Medical Affairs and Education: The company invests in programs aimed at educating healthcare professionals about sickle cell disease and the potential benefits of its therapies. This can include seminars, workshops, and collaborative initiatives with medical communities.
4. Regulatory Support: Emmaus provides support for navigating the complex regulatory landscape associated with developing and bringing new therapeutics to market. This involves working with health authorities on clinical trial approvals and product registrations.
In summary, Emmaus Life Sciences, Inc. is committed to addressing major public health challenges associated with rare diseases, particularly sickle cell disease. Through its innovative products and supportive services, the company seeks to enhance the quality of life for patients while working toward the development of new therapeutic options.
Segments
1. Sickle Cell Disease: This is the cornerstone of Emmaus Life Sciences research and commercial efforts. Sickle cell disease is a genetic blood disorder characterized by the deformity of red blood cells, leading to severe pain episodes and various complications. Emmaus seeks to address the unmet medical needs within this patient population.
2. Rare Disease Therapeutics: Beyond sickle cell anemia, Emmaus is interested in exploring treatments for other rare diseases, looking to expand its portfolio in the biopharmaceutical market while focusing on conditions with significant patient need and limited treatment options.
3. Research and Development (R&D): The R&D segment is critical to Emmaus, focusing on the clinical development of new therapeutics and the enhancement of existing products. The company actively engages in preclinical and clinical trials to vet potential drug candidates.
Products
1. Endari (L-glutamine oral powder): Endari is Emmaus’ flagship product, specifically developed for the treatment of sickle cell disease in adults and children aged five years and older. This product has been FDA-approved and is designed to decrease the frequency of sickle cell crises and related complications. It works by decreasing oxidative stress in sickle red blood cells and is recommended for routine use in patients with the condition.
2. Pipeline Products: Emmaus maintains a pipeline of potential therapies under development, aimed at addressing other complications of sickle cell disease and possibly other hematologic conditions. The specifics of these pipeline products can vary based on ongoing clinical trials and research outcomes.
3. Potential New Indications: The company is exploring potential additional uses for its existing products and candidates, recognizing that some therapies may have implications for multiple conditions. Ongoing research into the pharmacodynamics and therapeutic benefits of L-glutamine and other compounds may lead to the discovery of new indications.
Services
1. Patient Support Programs: Emmaus understands that navigating chronic conditions like sickle cell disease requires more than medication. The company offers services that support patients in managing their disease effectively. This includes educational resources, counseling, and assistance in accessing care.
2. Clinical Trials Participation: Emmaus often engages with healthcare providers and institutions to facilitate clinical trials for its therapies. This service extends to both medical professionals and patients, ensuring they have access to cutting-edge treatment options while contributing to the advancement of medical research.
3. Medical Affairs and Education: The company invests in programs aimed at educating healthcare professionals about sickle cell disease and the potential benefits of its therapies. This can include seminars, workshops, and collaborative initiatives with medical communities.
4. Regulatory Support: Emmaus provides support for navigating the complex regulatory landscape associated with developing and bringing new therapeutics to market. This involves working with health authorities on clinical trial approvals and product registrations.
In summary, Emmaus Life Sciences, Inc. is committed to addressing major public health challenges associated with rare diseases, particularly sickle cell disease. Through its innovative products and supportive services, the company seeks to enhance the quality of life for patients while working toward the development of new therapeutic options.